Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell-Free DNA Analysis of Targeted Genomic Regions in Maternal Plasma for Non-Invasive Prenatal Testing of Trisomy 21, Trisomy 18, Trisomy 13, and Fetal Sex

27 Apr 2016

Abstract excerpt

BACKGROUND: There is great need for the development of highly accurate cost effective technologies that could facilitate the widespread adoption of noninvasive prenatal testing (NIPT). METHODS: We developed an assay based on the targeted analysis of cell-free DNA for the detection of fetal aneuploidies of chromosomes 21, 18, and 13. This method enabled the capture and analysis of selected genomic regions of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27117469
DOI: 10.1373/clinchem.2015.252502

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell-Free DNA Analysis of Targeted Genomic Regions in Maternal Plasma for Non-Invasive Prenatal Testing of Trisomy 21, Trisomy 18, Trisomy 13, and Fetal SexPMID 27117469Read ↗

Clinical performance of non‐invasive prenatal testing (NIPT) using targeted cell‐free DNA analysis in maternal plasma with microarrays or next generation sequencing (NGS) is consistent across multiple controlled clinical studiesSemantic proximity Read ↗

Clinical validation of a novel automated cell‐free DNA screening assay for trisomies 21, 13, and 18 in maternal plasmaSemantic proximity Read ↗

Non‐invasive prenatal testing for fetal aneuploidy: charting the course from clinical validity to clinical utilitySemantic proximity Read ↗

Fetal fraction‐based risk algorithm for non‐invasive prenatal testing: screening for trisomies 13 and 18 and triploidy in women with low cell‐free fetal DNASemantic proximity Read ↗

Cell-free DNA Analysis for Noninvasive Examination of TrisomySemantic proximity Read ↗

Analysis of cell‐free <scp>DNA</scp> in maternal blood in screening for fetal aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Noninvasive Prenatal Testing for Fetal Trisomies in a Routinely Screened First-Trimester PopulationSemantic proximity Read ↗

Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysisSemantic proximity Read ↗

Cell-Free DNA Analysis for Trisomy Risk Assessment in First-Trimester Twin PregnanciesSemantic proximity Read ↗

Screening for trisomies 21, 18 and 13 by cell‐free <scp>DNA</scp> analysis of maternal blood at 10–11 weeks' gestation and the combined test at 11–13 weeksSemantic proximity Read ↗

Assessment of Fetal Sex Chromosome Aneuploidy Using Directed Cell-Free DNA AnalysisSemantic proximity Read ↗

Clinical Perspective of Cell-Free DNA Testing for Fetal AneuploidiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.